Dr. Wykoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4460 Bissonnet St
Ste 200
Bellaire, TX 77401Phone+1 713-524-3434Fax+1 713-524-3220
Summary
- Board Certified by the American Board of Ophthalmology. Partner at Retina Consultants of Houston & Clinical Assistant professor at Weill Cornell Medical College, Houston Methodist Hospital. Research interests: angiogenesis & exudative retinal diseases as well as vitreoretinal surgery topics including trauma, retinal detachments, diabetic retinopthay, & macular holes. Principle investigator on numerous clinical trials including novel approaches to treating AMD, RVO and diabetic retinopathy. Member of the Macula Society, ASRS, AAO, and ARVO.
Education & Training
- B Palmer Eye Institute - A B Leach EyeChief Residency, Chief Resident & Co-Director of Ocular Trauma, 2010 - 2011
- University of Miami Hospital and ClinicsFellowship, Surgical Retina and Vitreous, 2009 - 2011
- University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2006 - 2009
- Brigham and Women's HospitalInternship, Internal Medicine, 2005 - 2006
- Harvard Medical SchoolClass of 2005
Certifications & Licensure
- TX State Medical License 2011 - 2026
- FL State Medical License 2009 - 2015
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Start of enrollment: 2012 Oct 01
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab Start of enrollment: 2012 Dec 01
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsSensitivity analysis in clinical trials: three criteria for a valid sensitivity analysis.Sameer Parpia, Tim P Morris, Mark R Phillips, Charles C Wykoff, David H Steel
Eye. 2022-11-01 - 7 citationsEFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and H...Pravin U Dugel, Chirag D Jhaveri, Usha Chakravarthy, Charles C Wykoff, Rishi P Singh
Retina. 2022-03-01 - 3942 citationsThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisPatrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux
Nature. 1999-05-20
Journal Articles
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyCharles C Wykoff, Srinivas R Sadda, JAMA Ophthalmology
- Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging with Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLee M Jampol, Lloyd Paul Aiello, Jennifer K Sun, Szilard Kiss, Charles C Wykoff, Neil M Bressler, JAMA
Authored Content
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
Press Mentions
- Study of Alkeus' Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function ImprovementOctober 24th, 2024
- Experts Offer Guidance on Suprachoroidal Space Injections, the Newest Frontier in Retinal Drug DeliveryOctober 17th, 2024
- RGX-314 Gene Therapy Trial Shows Promise in Treating Wet Macular DegenerationAugust 13th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: